Author Archives: Bruno Quinney

Bristol Myers Squibb offices
#Bristol Myers Squibb #Clinical trial #Drug discovery

Bristol Myers Squibb extends Syngene partnership 

Bristol Myers Squibb has extended its long-term research collaboration with global CRDMO Syngene until 2035.  The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data, and information technology services, to enable seamless progression… Read More

#Business & Investment #News

Clinical trial
#Canada #UK #Vaccines

UK-Canadian partnership to advance vaccine technology 

A £750,000 ($1 million) global collaboration has been launched to advance next-generation vaccine technology.  iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium: iiCON, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models.   This £750,000… Read More

#Business & Investment #News

#Awards #FDA #University of California San Diego

CIRM awards $7.4m for novel Freidreich’s ataxia therapy 

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a first-of-its-kind stem cell-based gene therapy for Friedreich’s ataxia.  The funding, awarded to a team at the University of California San Diego, will help researchers complete the final steps required by federal regulators before they… Read More

#News

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Regulatory #UK government #University of California San Francisco #Women's health

DDW Highlights: 20 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research in women’s health uncovered significant findings related to endometriosis and… Read More

#Podcasts

Eye
#Beacon Therapeutics #Biotech #Ocular diseases

Beacon Therapeutics to advance ocular disease treatment 

Biotechnology company Beacon Therapeutics has raised over $75 million to advance treatments for ocular diseases.  The funding was raised in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of… Read More

#Business & Investment #News

Artificial Intelligence
#AI #AI / data analytics / healthtech / informatics #Drug discovery

Insitro acquires AI biotech to develop drug discovery platform 

AI therapeutics company insitro has acquired biotechnology company CombinAbleAI to complete its AI platform for drug discovery and design.   The platform, known as TherML (Therapeutic Machine Learning), will enable insitro to accelerate the generation of clinic-ready assets and reduce late-stage development risk. The company’s enhanced platform will reportedly guide both modality selection and molecular design from target discovery through developability assessment. … Read More

#Business & Investment #News

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Ovarian cancer #Regulatory #UK government #University of California San Francisco #Women's health

This week in Drug Discovery (12 – 16 January) 

News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW.  This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed?  The top stories:    Discovery reveals endometriosis is not… Read More

#News

European map
#BioInnovation Institute #Denmark #Europe #Life sciences #Novo Nordisk Foundation

Novo Nordisk Foundation pledges €736m for scientific innovation 

The Novo Nordisk Foundation has granted DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII) to support life sciences and scientific innovation in Denmark and Europe.  The funding will enable BII to expand its activities into new strategic areas and geographies, supporting even more entrepreneurs and start-up-companies.  … Read More

#Business & Investment #News

CAR-T cells attacking a cancer cell
#Advanced Therapies #Biotech #CAR T-cell therapy #CARsgen Therapeutics #Dispatch Bio

Biotech collaboration to develop CAR-T therapies 

Biotech companies Dispatch Bio and CARsgen Therapeutics have announced a clinical collaboration to develop innovative CAR-T cell therapies.  The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch’s Flare platform. This includes DV-10, the company’s novel tumour-specific virus, and CARsgen’s zevorcabtagene autoleucel (zevor-cel), an autologous B-cell maturation… Read More

#Business & Investment #News

Medical laboratory
#Clinical trial #Dermatology #JP Morgan Healthcare Conference

Almirall to initiate three clinical trials in dermatology field 

Global pharmaceutical company Almirall has announced it will launch three clinical trials in 2026 to further advances in the medical dermatology field.  Speaking at the 44th J.P. Morgan Healthcare Conference, which took place in San Francisco, Almirall CEO Carlos Gallardo said the company was focused on developing impactful novel… Read More

#News

Colorectal cancer
#Colorectal cancer #Gene mutation #Tumour biology

Gene mutation accelerates tumour growth in colorectal cancer 

A common gene mutation could be the cause of tumours forming in colorectal cancer patients, a new study suggests.  A team of researchers from ChristianaCare and the University of Delaware uncovered how a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal… Read More

#Cancer Research #News

#Antibody engineering #Financing #Nuclera

Nuclera raises $87m to advance antibody engineering 

Biotechnology company Nuclera has extended its Series C financing to $87 million to advance antibody engineering.  The financing round, led by Elevage Medical Technologies and Jonathan Milner, was extended by $12 million following earlier investment worth $75 million.  The funding is set to support Nuclera’s development of eProtein discovery for full-format antibody expression, purification and… Read More

#Business & Investment #News

FDA headquarters
#FDA #Sentynl Therapeutics

FDA approves first ever Menkes disease therapy 

The US Food and Drug Administration (FDA) has approved the first and only therapy for Menkes disease.  Zycubo (copper histidinate), developed by US biopharmaceutical company Sentynl Therapeutics, is a subcutaneous injectable formulation given daily to deliver elemental copper to the body.  In a pooled analysis of two… Read More

#News #Regulatory

Ovarian cancer cells
#CureLab Oncology #DNA #Oncology #Ovarian cancer

Therapy could increase ovarian cancer survival, paper finds 

A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals.  A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More

#Cancer Research #News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Rebecca Simmons as COO 

Techbio company Qureight has appointed Rebecca Simmons as the company’s Chief Operating Officer.  Simmons will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives. The appointment comes as Qureight aims to drive adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for… Read More

#News

#Biotech #Financing #Investment

$100m fund set up to invest in biotech companies 

Investment manager Arkin Capital has closed a $100 million financing round to set up Arkin Bio Ventures III, a $100m fund aimed at investing in biotech companies.  Arkin Bio Ventures III will back 10 to 12 pre-clinical to early clinical-stage biotech companies, developing transformative therapies in areas… Read More

#Business & Investment #News